ArriVent BioPharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AVBP research report →
Range $18 – $29
Price Chart
About the company
ArriVent BioPharma, Inc. , a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients.
- CEO
- Zhengbin Yao
- IPO
- 2024
- Employees
- 77
- HQ
- Newtown Square, PA, US
Get TickerSpark's AI analysis on AVBP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $544.13M
- P/E
- -2.87
- PEG
- -0.28
- P/S
- 108.83
- P/B
- 1.32
- EV/EBITDA
- -2.50
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -3620.02%
- Net Margin
- -3381.40%
- ROE
- -48.60%
- ROIC
- -45.97%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-177,534,000
- Net Income
- $-166,308,000-106.6%
- EPS
- $-4.32-68.8%
- OCF Growth
- -128.7%
- FCF Growth
- -128.7%
- 52W High
- $35.83
- 52W Low
- $10.33
- 50D MA
- $19.85
- 200D MA
- $26.25
- Beta
- 1.35
- RSI (14)
- 29
- Avg Volume
- 1.35M
No earnings-call transcripts are available for AVBP yet.
- Free Float
- 75.0%
- Shares Outstanding
- 51.72M
- Float Shares
- 38.82M
of shares held by institutions
166 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Montanova Capital, LLC | 4.52M | ▲ 114.45K |
| Infinitum Asset Management, LLC | 4.44M | ▲ 289.46K |
| Hhlr Advisors, Ltd. | 3.93M | 0 |
| Blackrock, Inc. | 3.41M | ▲ 156.92K |
| Orbimed Advisors LLC | 3.03M | 0 |
| Fmr LLC | 2.97M | ▲ 188.04K |
| Vanguard Capital Management LLC | 2.01M | ▲ 236.38K |
| Octagon Capital Advisors LP | 1.97M | 0 |
| Vanguard Group Inc | 1.87M | ▼ 160.26K |
| Vivo Capital, LLC | 1.79M | ▲ 105.01K |
| State Street Corp | 1.76M | ▲ 70.11K |
| Sofinnova Investments, Inc. | 1.70M | 0 |
Held by 217 ETFs
Biggest fund positions in AVBP by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 30, 26 | LaChapelle Robin | other | 17,648 |
| Oct 30, 26 | LaChapelle Robin | other | 1,820 |
| Oct 30, 26 | LaChapelle Robin | other | 4,550 |
| Oct 30, 26 | LaChapelle Robin | other | 410 |
| Oct 30, 26 | LaChapelle Robin | other | 16,265 |
| Oct 30, 26 | LaChapelle Robin | other | 17,648 |
| Oct 30, 26 | LaChapelle Robin | other | 16,265 |
| Oct 30, 26 | LaChapelle Robin | other | 4,550 |
| Oct 30, 26 | LaChapelle Robin | other | 1,820 |
| Jun 18, 26 | Parsey Merdad | other | 13,562 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AVBP coverage
Recent articles, reports, and earnings notes.
No research on AVBP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AVBP report →ArriVent BioPharma: ARR-217 Gives Us A Reason To Reconsider Our Strong Sell (Rating Upgrade)
seekingalpha.com · Nov 15
ArriVent BioPharma Reports Third Quarter 2026 Financial Results
globenewswire.com · Nov 9
Aarvik Therapeutics Announces Milestone Achievement, Partnership Update, and Presentations on MUTTA™ and AQUALINK™ Platforms at the 17th Annual WADC Conference
businesswire.com · Nov 2
Arrivent Biopharma Investigation Continues: Investors May Contact Kirby McInerney LLP, a Securities Fraud Law Firm, If You Lost Money On Your AVBP Investments
newsfilecorp.com · Oct 28
ArriVent BioPharma's ARR-217 Shows 44.8% Response Rate in Colorectal Cancer Study
marketbeat.com · Oct 27
ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026
globenewswire.com · Oct 25
ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026
globenewswire.com · Oct 23
ARRIVENT BIOPHARMA AVBP INVESTORS: Contact Kirby McInerney LLP About the Firm's Securities Investigation Following 47.3% Share Drop
businesswire.com · Oct 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.